MA13.08 Genomic and Transcriptomic Features of Distinct Resistance Trajectories in EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)

Despite the established role of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in advanced EGFR mutant NSCLC, drug resistance inevitably ensues. More than 40% of resistant patients are EGFRT790M negative (T790M-), for which a diverse range of mechanisms have been described and there remains a paucity of treatment options. Here, we performed systematic multi-omics profiling and analysis of first- and second-generation (1G/2G) TKI resistant patients to better understand molecular features of EGFRT790M positive (T790M+) and T790M- disease.